HC Wainwright started coverage on shares of Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) in a research note published on Monday morning. The firm issued a buy rating and a $5.00 price objective on the specialty pharmaceutical company’s stock.

Separately, Rodman & Renshaw assumed coverage on shares of Imprimis Pharmaceuticals in a research report on Monday. They set a buy rating and a $5.00 target price on the stock.

Imprimis Pharmaceuticals (NASDAQ:IMMY) remained flat at $2.94 on Monday. 97,151 shares of the company traded hands. Imprimis Pharmaceuticals has a 52 week low of $2.22 and a 52 week high of $7.81. The firm’s market capitalization is $38.96 million. The firm has a 50 day moving average of $2.78 and a 200 day moving average of $3.61.

TRADEMARK VIOLATION NOTICE: “Imprimis Pharmaceuticals Inc. (IMMY) Now Covered by Analysts at HC Wainwright” was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/29/imprimis-pharmaceuticals-inc-immy-now-covered-by-analysts-at-hc-wainwright.html.

Institutional investors have recently added to or reduced their stakes in the stock. Berson & Corrado Investment Advisors LLC purchased a new position in Imprimis Pharmaceuticals during the second quarter worth approximately $117,000. BlackRock Fund Advisors raised its position in Imprimis Pharmaceuticals by 59.5% in the second quarter. BlackRock Fund Advisors now owns 32,979 shares of the specialty pharmaceutical company’s stock worth $124,000 after buying an additional 12,300 shares during the period. Northern Trust Corp raised its position in Imprimis Pharmaceuticals by 4.1% in the third quarter. Northern Trust Corp now owns 45,467 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 1,800 shares during the period. Granite Investment Partners LLC raised its position in Imprimis Pharmaceuticals by 3.7% in the third quarter. Granite Investment Partners LLC now owns 160,876 shares of the specialty pharmaceutical company’s stock worth $613,000 after buying an additional 5,686 shares during the period. Finally, Vanguard Group Inc. raised its position in Imprimis Pharmaceuticals by 1.7% in the second quarter. Vanguard Group Inc. now owns 168,584 shares of the specialty pharmaceutical company’s stock worth $634,000 after buying an additional 2,831 shares during the period. Hedge funds and other institutional investors own 24.85% of the company’s stock.

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.

5 Day Chart for NASDAQ:IMMY

Receive News & Stock Ratings for Imprimis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.